Supplemental Figure 1: Patient disposition (all women). AE, adverse event; b.i.d., twice daily; ITT, intent-to-treat. All randomized patients (N=2939)ITT population: ITT population: Randomized to Randomized to tegaserod 6 mg b.i.d. placebo b.i.d. (n=1459)(n=1478)Safety population: Safety population: (n=1364)(n=1477)Discontinued (n=268) Discontinued (n=286) • AE(s), n=74 (5.1%) • AE(s), n=97 (6.6%) · Patient withdrew consent. · Patient withdrew consent. n=86 (5.9%) n=84 (5.7%) • Lost to follow-up, n=57 (3.9%) • Lost to follow-up, n=40 (2.7%) Unsatisfactory therapeutic effect. Unsatisfactory therapeutic effect. n=49 (3.4%) n=24 (1.6%) • Protocol violation, n=10 (0.7%) • Protocol violation, n=12 (0.8%) Abnormal laboratory value(s), Abnormal laboratory value(s), n=5 (0.3%) n=7(0.5%)· Administrative problems, Administrative problems, n=4 (0.3%) n=4 (0.3%) Patient condition no longer requires study drug, n=1 (0.1%) Completed study Completed study

(n=1175)

(n=1210)